A simple blood test for early detection of lung cancer
Our test uses the body’s immune response to detect all types of lung cancer from the earliest stages of the disease
What is EarlyCDT—Lung?
EarlyCDT—Lung is a simple blood test that takes advantage of the body’s immune response to the presence of cancer. The test detects autoantibodies to tumour-associated antigens (substances that trigger an immune response against them), that are often present in the blood from the earliest stages of lung cancer.
An autoantibody is an antibody made against substances formed by a person’s own body.1
An antibody is a protein made by plasma cells (a type of white blood cell) in response to an antigen.2
An antigen is a substance that causes the body to make a specific immune response.2
EarlyCDT—Lung measures blood levels of seven autoantibodies that are often produced by the body in response to lung cancer.
EarlyCDT—Lung is quick and convenient. Your clinician may ask you to prick your finger with the “finger stick” we supply, and place a few drops of blood into a small container; or he or she may advise you to have a blood draw with a phlebotomist.
Your blood sample is analyzed in our laboratory in Kansas, which then sends the test results back to your clinician within 2 to 5 days.
Your clinician will discuss the test results with you and recommend the best approach to treatment.
Am I a candidate for EarlyCDT—Lung?
EarlyCDT—Lung is for patients who have pulmonary nodules (growths or lumps in lung tissue that may be malignant or benign) that have an intermediate risk of developing into lung cancer. By helping doctors assess the risk of lung cancer, the test can allow for earlier detection and diagnosis of the disease, and for timely initiation of effective treatment.
If you have one or more nodules in your lung that have been identified by CT scan or X-ray, and if your doctor assesses the risk of cancer in any nodule as 5% or greater, then you are a candidate for EarlyCDT—Lung.
Your doctor can use the test to decide whether it is better to start treatment quickly, or to remain in “watchful waiting” mode to see if your nodule changes in size or appearance — a sign that may indicate cancer.
EarlyCDT—Lung is only suitable for you if your risk of cancer is greater than 5%, in which case it can play a crucial role in detecting early-stage disease. The test’s positive High or Moderate Level results mean that cancer is significantly more likely and may indicate the need for potentially curative surgery without delay. Treating lung cancer early increases the chance of survival.
You should trust your clinician to assess your suitability for EarlyCDT—Lung. Although most nodules are benign, the test is suitable for patients who have nodules that indicate considerable clinical uncertainty. Your clinician is in the best position to consider the many different factors that determine your suitability for the test.
Am I covered?
Oncimmune is committed to making EarlyCDT—Lung accessible to all patients who have indeterminate pulmonary nodules.
EarlyCDT—Lung is not a molecular diagnostic test, but an immunoassay: a test that uses the binding of antibodies to antigens to identify and measure certain substances, and which may be used to diagnose or provide other information about a disease.1 That makes the test relatively inexpensive.
Oncimmune works with all insurance carriers.
As a Medicare provider, Oncimmune files claims for beneficiaries being tested.
Qualified Medicare claims are typically covered at 100%, but may be subject to co-pay, co-insurance, and/or unmet deductible.
Insurance & Medicare Advantage Plans:
While Oncimmune is out-of-network with commercial insurance payers, we actively work with all payers to seek coverage of the test within your plan.
Does your insurance cover out-of-network laboratory tests?
Does your insurance require a pre-authorization, or a referral for out-of-network benefits?
Does your insurance require the authorization to be obtained before the test is ordered or before having your blood drawn?
The allowed charges specified on the insurance EOB could be subject to co-pays, co-insurance and/or unmet deductibles, and will be invoiced to you by Oncimmune.
Self-Pay is available for uninsured or for patients who wish to pay directly out-of-pocket. Please contact our Client Services team for further information.
Oncimmune will not submit a claim to your health insurance.
Patients opting for Self-Pay must do so prior to Oncimmune performing the tests.
1 NCI Dictionary of Cancer Terms. U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute, 2018. https://www.cancer.gov/publications/dictionaries/cancer-terms/search?contains=false&q=immunoassay
Insurance and Billing Questions
If you are denied insurance coverage or have insurance/billing questions, we encourage you to reach out to our client services department for help. Please email firstname.lastname@example.org or call (866) 432 5930.
How do I get EarlyCDT—Lung?
EarlyCDT—Lung has to be ordered by a clinician.
Your clinician must assess your suitability for EarlyCDT—Lung, interpret the test results, and advise on follow up care.
Lung Cancer Symptoms
In the early stages of lung cancer, there are often no signs or symptoms of the disease. These symptoms tend to develop as the lung cancer becomes more advanced.
The most common lung cancer symptoms are1:
A cough that does not subside or becomes worse
Coughing up blood, spit or phlegm
Chest pain that often grows worse with coughing, deep breathing and laughing
Loss of weight and appetite
Being tired or weak
Shortness of breath
Infections like pneumonia or bronchitis that don’t subside or continue to come back
If you have any signs or symptoms of lung cancer, you should see your doctor as soon as possible. EarlyCDT—Lung is only suitable for you if you have an intermediate risk pulmonary nodule found on CT scan or XRay.
Lung cancer risk factors
One or more of these factors can increase your lung cancer risk:
Smoking, especially of heavy tar in tobacco cigarettes and marijuana
Close relatives with lung cancer
Extended exposure to secondhand smoke
Exposure to asbestos, radon, coal products and/or radioactive substances
Exposure to chemicals like vinyl chloride, arsenic and other carcinogens
Diagnosis of silicosis, tuberculosis and/or berylliosis with or without scars on the lung
Pneumonia or bronchitis that continuously reoccurs